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Objective: The effect of surgical treatment for supratentorial spontaneous intracerebral hemorrhage (ICH) and whether
it is modified by key baseline characteristics and timing remains uncertain.
Methods: We performed a systematic review and meta-analysis of randomized controlled trials of surgical treatment of
supratentorial spontaneous ICH aimed at clot removal. We searched MEDLINE, Embase, and Cochrane databases up
to February 21, 2019. Primary outcome was good functional outcome at follow-up; secondary outcomes were death
and serious adverse events. We analyzed all types of surgery combined and minimally invasive approaches separately.
We pooled risk ratios with 95% confidence intervals and assessed the modifying effect of age, Glasgow Coma Scale,
hematoma volume, and timing of surgery with meta-regression analysis.
Results: We included 21 studies with 4,145 patients; 4 (19%) were of the highest quality. Risk ratio of good functional
outcome after any type of surgery was 1.40 (95% confidence interval [CI] = 1.22–1.60, I2 = 46%, 20 studies), and after
minimally invasive surgery it was 1.47 (95% CI = 1.26–1.72, I2 = 47%, 12 studies). For death, the risk ratio for any type
of surgery was 0.77 (95% CI = 0.68–0.85, I2 = 23%, 21 studies), and for minimally invasive surgery it was 0.68 (95%
CI = 0.56–0.83, I2 = 14%, 13 studies). Serious adverse events were reported infrequently. Surgery seemed more effec-
tive when performed sooner after symptom onset (p = 0.04, 12 studies). Age, Glasgow Coma Scale, and hematoma
volume did not modify the effect of surgery.
Interpretation: Surgical treatment of supratentorial spontaneous ICH may be beneficial, in particular with minimally
invasive procedures and when performed soon after symptom onset. Further well-designed randomized trials are
needed to demonstrate whether (minimally invasive) surgery improves functional outcome after ICH and to determine
the optimal time window of the treatment after symptom onset.
ANN NEUROL 2020;00:1–12
Acute nontraumatic spontaneous intracerebral hemor-rhage (sICH), accounts for 15 to 20% of all strokes
in the Western population and for 20 to 50% in
developing countries.1–3 ICH is the deadliest stroke sub-
type, with a 30-day case fatality of approximately 40%.4
Rapid identification and treatment are essential to
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facilitate recovery.5 However, of patients surviving, only
few gain independence.4,6 Apart from the effect of stroke
unit care7 and early control of elevated blood pressure,
which may be beneficial,8,9 there are no treatments with
proven benefit.5,10,11 A recent study showed that imple-
mentation of a hyperacute care bundle (anticoagulation
reversal, intensive blood pressure lowering, neurosurgery
in selected patients, access to critical care), reduces case
fatality.12
The role of surgery in supratentorial sICH remains
controversial.13,14 This is reflected in the American and
European guidelines, which refrain from giving firm
advice regarding the role of surgery in ICH. As a result,
there is large variation in clinical practice.11 The landmark
trials STICH and STICH II failed to demonstrate a bene-
ficial effect of surgical treatment, mostly craniotomy, but
surgery was performed late, on average 30 hours after
symptom onset in STICH15 and 27 hours in STICH II.16
In the STICH trials, crossover from the control arm to
surgery was allowed if a patient deteriorated. Increasing
evidence suggests that with minimally invasive procedures
the potentially adverse effect of open surgery in patients
with sICH can be avoided and a beneficial effect on func-
tional outcome may be achieved. An individual patient
data meta-analysis of randomized controlled trials (RCTs)
published up to 2010 suggested that the effect of surgery
may be modified by the clinical state of the patient and
the timing of surgery, but in this analysis only a minority
of patients were treated with minimally invasive tech-
niques.17 Recently, the MISTIE III trial showed that min-
imally invasive hematoma aspiration with local application
of alteplase up to 72 hours after surgery did not seem to
be superior to standard medical care.18 However, surgery
in this trial was also performed late, on average 58 hours
after symptom onset.18
Approximately one-quarter of patients with ICH
show hematoma growth, with the highest probability of
growth within the first 3 hours after symptom onset.19
Besides the direct brain injury by compression and disrup-
tion of parenchyma, sICH elicits a secondary response.
This secondary brain injury results from toxicity due to
blood degradation products (eg, heme, iron) and plasma-
derived components (eg thrombin), which starts within
3 to 4 hours after sICH, causing an inflammatory
response and the development of perihematomal edema.20
Hematoma volume, hematoma growth, and peri-
hematomal edema are independent predictors of poor out-
come.21,22 Targeting hematoma growth, inflammation,
and perihematomal edema at an early stage after sICH
may reduce not only hematoma volume but also second-
ary brain injury, and could possibly improve outcome.
However, a previous pilot study of “ultra-early” surgery
within 4 hours after sICH in 20 patients was stopped
early after a planned interim analysis in 11 patients
because of postoperative bleeding in 4 patients, in 3 of
them fatal.23 Others found no difference in rebleeding
rates between stereotactic treatment within (mean = 4.8 h,
32 patients, 1 rebleed), or after 6 hours (mean = 13.8 h,
27 patients, 2 rebleeds) from symptom onset in computed
tomography (CT) angiographic spot sign–negative
patients, suggesting that early surgery may be safe in
patients with ICH in the absence of a spot sign.24
We aimed to systematically review and meta-analyze
RCTs of surgical treatment of supratentorial sICH aimed
at clot removal, both overall and for minimally invasive
treatment separately, and to assess the modifying effect of
age, Glasgow Coma Score (GCS), hematoma volume, and
timing of surgery.
Patients and Methods
We adhered to the PRISMA guidelines25 and registered
the study protocol in PROSPERO (CRD42018098864).
Search Strategy and Selection Criteria
We searched MEDLINE, Embase, and Cochrane databases
up to February 21, 2019. We included RCTs on the effect
of neurosurgical hematoma evacuation, compared with stan-
dard medical management on functional outcome and death,
in adult patients (≥18 years of age) with a CT or magnetic
resonance scan-confirmed supratentorial sICH. Neurosurgical
intervention could consist of craniotomy, craniopuncture,
stereotactic aspiration, endoscopy-guided aspiration with or
without local clot mobilization techniques using thrombo-
lytic agents, or alternative methods. Treatment of hydroceph-
alus with extraventricular drainage (EVD) alone was not
included as an intervention of interest and was allowed in
both groups. Duration of follow-up in the trial had to be at
least 3 months. We excluded studies that included patients
with secondary causes of ICH (ie, hemorrhage due to
trauma, aneurysm, arteriovenous malformation and dural
arteriovenous fistula, cavernous malformation and tumor) or
infratentorial hemorrhages (unless separately reported) and if
≥15% of the surgical interventions were decompressive
hemicraniectomies without hematoma removal. Conference
abstracts were excluded. We did not apply any language
restriction. The search strategy consisted of terms for (sup-
ratentorial) ICH and terms for surgical treatment or hema-
toma evacuation. We identified further studies from the
reference lists of included papers and screened reference lists
of review articles. Finally, we searched ClinicalTrials.gov, the
International Standard Randomized Controlled Trial Num-
ber registry, and the https://www.isrctn.com/ database for
clinical trials, and ClinicalTrialsRegister.eu for unpublished
studies.
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Two authors (L.S. and F.H.B.M.S.) independently
screened the abstracts and assessed full texts to identify
studies that potentially met the predefined inclusion and
exclusion criteria. Any disagreements between these
authors were resolved by a third reviewer (C.J.M.K.). For
articles written in Chinese, we received help from 2 native
Chinese colleagues.
Data Synthesis and Statistical Analyses
Two authors (L.S. and F.H.B.M.S.) independently
extracted data from the included studies, using a standard-
ized, prepiloted form, and assessed the risk of bias using
the following items from the Cochrane criteria: random
sequence generation, allocation concealment, blinding of
outcome assessment, incomplete outcome data, selective
reporting, and performance of an intention-to-treat analy-
sis.26 Because blinding to treatment of participants and
personnel is not feasible in a neurosurgical trial, we dis-
carded this item. Disagreements on extracted data were
resolved by discussion with a third reviewer (C.J.M.K.).
We extracted the following baseline characteristics:
sex, mean or median age and age range, clinical condition
on admission measured by the mean or median GCS and
range, proportion with a history of hypertension, ICH
location, mean or median ICH volume and range, pres-
ence of intraventricular hemorrhage, surgical technique,
mean or median time from symptom onset to surgery and
range, and proportion of patients who crossed over from
control to intervention.
The prespecified primary outcome was good func-
tional outcome at 3-month follow-up. Because the timing
of the primary outcome event in the included studies var-
ied from 3 to 12 months, we assessed whether the effect
size of surgery differed in studies reporting outcomes at
3, 6, and 12 months. Because the estimates of surgery
appeared similar for all time points, we combined all stud-
ies, using 6 months as the preferred time point (available
in most studies), and we used 3 or 12 months if the
6-month outcome was not provided. We defined good
functional outcome as a modified Rankin Scale score of
0 to 3, a Glasgow Outcome Scale score of 4 to 5, an
extended Glasgow Outcome Scale score of 5 to 8, or a
Barthel Index (BI) of ≥60. In studies that did not report
any of these outcomes, we used the scale and cutoff points
for good functional outcome as reported by the authors.
Secondary outcomes were death at 6 months
(or when not available at 3 or 12 months), case fatality at
30 days, and serious adverse events within 30 days,
including rebleeding, epileptic seizures, intracranial infec-
tion, hydrocephalus, severe systemic infection, gastrointes-
tinal bleed, need for (repeated) surgical intervention,
and EVD.
We calculated risk ratios (RRs) with 95% confidence
intervals (CIs) for good functional outcome and death at
the time of follow-up, using a random effects model for
all surgical procedures, for studies on minimally invasive
surgery, and for studies on (>99%) craniotomy. We per-
formed a sensitivity analysis assessing high-quality studies
only, defined as studies with a low risk of bias on all items
as determined by the Cochrane risk of bias tool. We
assessed heterogeneity by means of the I-squared statistic
(I2) and categorized heterogeneity as follows: 0 to 40%,
heterogeneity that might not be important; 30 to 60%,
moderate heterogeneity; 50 to 90%, substantial heteroge-
neity; and 75 to 100%, considerable heterogeneity. In
addition, we calculated prediction intervals, which help in
the clinical interpretation of heterogeneity by estimating
the expected range of true effects in similar studies. They
can be used as a tool for interpreting evidence and enable
more informed clinical decision-making.27 We performed
a sensitivity analysis for good functional outcome at
follow-up, excluding the 2 studies that used BI as out-
come measure. We constructed funnel plots to evaluate
potential publication bias.
We performed meta-regression analysis for the pri-
mary outcome to assess the effect of 4 prespecified factors
that have previously been suggested to influence the effect
of surgery15–17: age (mean, or when not available median
age), GCS (median, or when not available mean GCS),
time from symptom onset to surgery, and ICH volume
(mean, or when not available median ICH volume). We
performed meta-regression for these potential modifying
factors only if there were at least 10 studies available that
reported that specific factor; further multivariate meta-
regression analysis was performed if at least 10 studies
were available for every modifying factor included (eg,
20 studies for analysis of 2 factors).26,28,29 In addition, we
assessed the effect of surgery in subgroups according to
ICH location (lobar vs nonlobar), because the effect of
surgery appeared to be different in lobar than in deep
ICH in STICH.15 Finally, we summarized the reported
percentages of adverse events.
We used the software program R and R-studio ver-
sion 3.4.4, packages “meta,” “metafor,” and “foreign.”
Results
We identified 21 studies (Fig 1) including 4,145 patients, of
whom 2,091 were randomized for neurosurgical hematoma
evacuation and 2,054 patients for standard medical manage-
ment. One eligible study did not provide data on functional
outcome and was excluded for the meta-analysis on good
functional outcome.30 The Table summarizes the characteris-
tics of the included studies. Inclusion criteria for the
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individual RCTs are listed in the supplement (Supplemen-
tary Table 4). Of the 21 studies, 13 studies assessed mini-
mally invasive surgical approaches,18,30–32,36–42,44,45 in 6 of
them in combination with a thrombolytic
agent.18,31,37,41,42,45 One study included patients with lobar
ICH only,16 and 7 studies were restricted to patients with
deep ICH.30,34,38,39,41,42,44 Nine studies specified whether
thalamic hemorrhages were included.16,18,31,33–36,39,43 Four
studies included 12 to 23% thalamic hemorrhages,33,35,36,39
and 3 did not include thalamic hemorrhages.16,34,43 Intra-
ventricular extension of ICH was an exclusion criterion in
1 study.16 Quality of studies was low in
9 studies,30,32,34–36,38–40,45and moderate in
8 studies.33,37,41–44,46,47 Only 4 studies were of high
quality,15,16,18,31 of which 2 investigated minimally invasive
surgery (Fig 2).18,31 The funnel plot suggested possible pub-
lication bias for smaller studies demonstrating results in
favor of medical management (Fig 3). Six to 26% of
patients randomized for standard medical management
crossed over to surgical hematoma evacuation (10 stud-
ies).15,16,18,31,33,38,39,41,43,46 Data on functional outcome
were available in 1,967 (99.5%) patients randomized to
surgery and in 1,919 (99.3%) patients randomized to
standard medical management. After surgical treatment,
the chance of good functional outcome was 40% higher
than after medical management (RR = 1.40, 95%
CI = 1.22–1.60, I2 = 46%; Fig 4). Estimates for sub-
groups of studies with outcome assessment at 3, 6, and
12 months are listed in Appendix S1 (see Supplementary
Table 1). Surgical treatment also lowered the risk of
death (RR = 0.77, 95% CI = 0.68–0.85, I2 = 21%,
FIGURE 1: Study selection.
FIGURE 2: Risk of bias assessment of included studies
(n = 21). From left to right: high, medium, low risk of bias.
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21 studies) at the time of follow-up. The RR for 30-day
case fatality after any type of surgery was 0.68 (95%
CI = 0.51–0.92, I2 = 0%, 5 studies). The chance of good
functional outcome after minimally invasive surgery was
47% higher than after medical management (RR = 1.47,
95% CI =1.26–1.72) with moderate heterogeneity
(Fig 5). Estimates for subgroups of studies with outcome
assessment at 3, 6, and 12 months were similar. Mini-
mally invasive surgery lowered the risk of death
(RR = 0.68, 95% CI = 0.56–0.83, I2 = 14%, 13 studies)
at the time of follow-up. The RR for 30-day case fatality
after minimally invasive surgery was 0.65 (95%
CI = 0.41–1.02, I2 = 0%, 3 studies). In studies investi-
gating craniotomy, RR for good functional outcome after
surgery was 1.44 (95% CI = 0.69–2.93, I2 = 48%,
6 studies), RR for death was 0.79 (95% CI = 0.66–0.94,
I2 = 0%, 6 studies), and RR for 30-day case fatality was
0.73 (95% CI = 0.46–1.15, I2 = 26%, 2 studies; Supple-
mentary Table 2). When we restricted the analyses to
high-quality studies (2 studies assessing mostly
FIGURE 3: Funnel plot assessing potential publication bias in included studies assessing good functional outcome at follow-up.
FIGURE 4: Effect of any type of surgery compared with standard medical management on good functional outcome in patients
with supratentorial spontaneous intracerebral hemorrhage. Functional outcome was assessed at 6 months after inclusion if
available. For 3 studies (Hattori 2004, Pantazis 2006, and Hanley 2019), functional outcome at 12 months after inclusion was
used, and for 4 studies (Zuccarello 1999, Wang 2009, Wei 2010, Bhaskar 2017), functional outcome at 3 months after inclusion
was used. CI = confidence interval; RR = risk ratio.
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TABLE. Baseline Characteristics of 21 Randomized Controlled Trials Meeting Inclusion Criteria
Study
P,
n
C,
n Type of Surgery
Use of Thrombolytic
Agent, % of Patients
Age,
Mean
yr
Male,
n (%)
GCS,
Median
(IQR)
Deep
ICH,
n (%)
Onset to
Surgery,
Mean h
IVH,
n (%)
Auer 198936 50 50 Endoscopy-guided No NR 61 (61) NR 55 (55) NR NR
Juvela 198935 26 26 Craniotomy NA 52 30 (58) 12 (7–14) 44 (85) 14.5a 32 (62%)
Batjer199034 8 13 Craniotomy NA 55 NR NR 21 (100) NR NR
Morgenstern
199846
17 17 Craniotomy NA 51b 22 (65) 11 (10–14) 26 (76) 8.3a NR
Zuccarello
199933
9 11 Craniotomy, n = 5;
stereotactic, n = 4
Urokinase in stereotactic 62 11 (55) 12 (9–14) 10 (50) 8.6a 11 (55%)
Teernstra
200337
36 34 Stereotactic Urokinase (100%) 68 40 (57) 9 (7–11) 32 (46) 12 23 (33%)
Hattori
200444
121 121 Stereotactic No 61 148 (61) NR 242 (100) NR NR
Mendelow
200515
503 530 Craniotomy 75% NR 62b 591 (57) 12 (9–14) 434 (42) 30a NR
Pantazis
200643
54 54 Craniotomy NA 61 60 (56) 9c 57 (53) 6.2a NR
Cho 200830 113 113 Endoscopy-guided No 63 151 (67) 11 226 (100) NR 72 (32%)
Luo 200839 36 39 Aspiration No 55 44 (59) NR 75 (100) NR NR
Miller
200840
6 4 Endoscopy-guided No 59 9 (90) NR 1 (10) 18 6 (60%)
Young
200941
204 183 Stereotactic Urokinase in 26% 66 289 (75) 14 (14–15) 387 (100) NR NR
Wang 200942 195 182 Stereotactic Urokinase (100%) 56 236 (63) 12 (10–14) 377 (100) 21 70 (19%)
Wei 201045 67 39 Various techniquesd Urokinase (100%) 57b 58 (55) NR NR (60) NR NR
Wang 201138 32 30 Craniopuncture No 46 34 (55) NR 62 (100) 8.2 NR
Mendelow
201316
305 292 Craniotomy 99% NA 64 340 (57) 13 (12–15) 0 (0) 26.7 0 (0%)
Hanley
201631
54 42 Stereotactic Alteplase (85%) 61 63 (66) NR 63 (66) NR NR
Vespa 201632 14 42 Endoscopy-guided No NR 37 (66) NR 39 (70) 29.9a NR
Bhaskar
201747
34 27 Craniotomy NA 55 37 (61) NR 52 (85) NR 31 (51%)
Hanley
201918
250 249 Stereotactic Alteplase (94%) NR 305 (61) 62 (52–70) 307 (62) 58.3 NR
aMedian time between symptom onset and surgery.
bData reported as median age.
cData reported as mean GCS.
dSmall skull window microsurgery was performed in 31 patients and minimally invasive surgery fragmenting and aspirating hematoma in 36 patients.
C = controls; GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; IQR = interquartile range; IVH = intraventricular hemorrhage; NA = not
applicable; NR = not reported; P = patients, surgically treated.
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FIGURE 5: Effect of minimally invasive surgery compared with standard medical management on good functional outcome in
patients with supratentorial spontaneous intracerebral hemorrhage. Functional outcome was assessed at 6 months after
inclusion if available. For 2 studies (Hattori 2004 and Hanley 2019), functional outcome at 12 months after inclusion was used,
and for 2 studies (Wang 2009 and Wei 2010), functional outcome at 3 months after inclusion was used. CI = confidence interval;
RR = risk ratio.
FIGURE 6: Effect of any type of surgery compared with standard medical management on good functional outcome in patients
with supratentorial spontaneous intracerebral hemorrhage in high-quality studies only. Functional outcome was assessed at
6 months after inclusion, except for 1 study (Hanley 2019) in which functional outcome at 12 months after inclusion was used. CI
= confidence interval; RR = risk ratio.
FIGURE 7: Influence of timing of surgery on the effect of surgery on good functional outcome. β = −0.0063, p = 0.04. Mean or, if
not available, median time from symptom onset to surgery was used to assess the influence of time from symptom onset to
surgery on the effect of any type of surgery on good functional outcome, in 12 studies. The size of each circle is proportional to
the precision of each log risk ratio estimate. MIS = minimally invasive surgery.
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craniotomy,15,16 2 assessing stereotactic surgery,18,31
including a total of 2,166 patients), RRs for good func-
tional outcome (RR = 1.10, 95% CI = 0.98–1.25,
I2 = 0%; Fig 6) and death (RR = 0.86, 95%
CI = 0.72–1.03, I2 = 3%, 4 studies) no longer showed a
statistically significant effect of surgical treatment.
Sensitivity analyses excluding 2 studies that used BI as
outcome measure42,46 showed similar results for the
chance of good functional outcome at follow-up (any
type of surgery: RR = 1.43, 95% CI = 1.22–1.69,
I2 = 51%, 18 studies; minimally invasive surgery:
RR = 1.54, 95% CI = 1.27–1.87, I2 = 49%, 11 studies).
We found no statistically significant modifying influ-
ence of age (18 studies, p = 0.61), GCS score on admission
(13 studies, p = 0.97), or ICH volume (15 studies, p = 0.50)
on good functional outcome at the time of follow-up (Sup-
plementary Table 3). Surgery seemed more effective than
medical management alone when performed sooner after the
onset of symptoms (12 studies, p = 0.04; Fig 7). We
found no modifying effects of age (19 studies, p = 0.43),
GCS (14 studies, p = 0.29), ICH volume (15 studies,
p = 0.32), or timing of surgery (12 studies, p = 0.37) on
death. Because any combination of modifying factors was
reported in <20 studies, we refrained from further multi-
variate meta-regression analysis.26,28,29 The number of
studies that assessed minimally invasive surgery and reported
modifying factors was <10, which precluded meta-regression
analysis in this subgroup. In the subgroup of patients with
deep ICH, the RR of good functional outcome after surgery
compared to medical management was 1.51 (95%
CI = 1.31–1.75, I2 = 25%, 9 studies), and in those with lobar
hemorrhages it was 1.25 (95% CI = 0.92–1.71, I2 = 13%,
4 studies). Reporting of adverse and serious adverse events var-
ied among studies (Supplementary Table 5). In surgically
treated patients, a second surgical procedure was needed in
4 to 16% of patients (5 studies).15,18,31,33,41 Rebleeding
occurred in 0 to 50% of medically treated patients
(12 studies),16,18,31–33,36,38–40,42,43,45 and in 0 to 35% of sur-
gically treated patients (13 studies).16,18,31–33,36–40,42,43,45
Three studies reported a higher frequency of rebleeds in the
group randomized to medical management than in those
who received surgery,16,36,45 whereas 5 studies found more
rebleeds in the group that underwent hematoma evacua-
tion.18,31,32,37,42 Four of these 5 studies used local applica-
tion of a thrombolytic agent to optimize the evacuation of
the hematoma.18,31,37,42 Operative site infections were
rare.18,31–33,38
Discussion
Our meta-analysis shows that neurosurgical hematoma evac-
uation in patients with supratentorial sICH holds promise
to improve functional outcome and death at 3 to
12 months, but only the minority of studies was without
bias. The effect of hematoma evacuation appears most
prominent with application of minimally invasive techniques
and when performed sooner rather than later after symptom
onset. We found no modifying effect of age, clinical state
on admission, and ICH volume. In the 4 RCTs of high
quality, the effect of neurosurgical hematoma evacuation on
functional outcome and on death was no longer statistically
significant.
One of the important factors for why earlier high-
quality RCTs may have failed to demonstrate a beneficial
effect of surgical hematoma evacuation for supratentorial
sICH is the timing of the surgical treatment. In the previous
individual patient data meta-analysis of RCTs published up
to 2010 that suggested that earlier surgery may increase the
benefit of intervention, the time interval between symptom
onset and randomization in the included studies was still
long.17 Approximately 40% of patients who had a known
time interval from onset to randomization were randomized
within 8 hours, approximately 30% between 8 and
24 hours, and approximately 30% >24 hours after symptom
onset. Time intervals between symptom onset and surgery
were not reported, but most likely only few patients will have
had their hematoma evacuation within 6 hours after symp-
tom onset in all trials, and even fewer within 3 hours
after symptom onset.48 Compared to the individual patient
data meta-analysis, we were able to include more
studies,16,18,30–32,34,38–41,43–45,47 among which are studies
with earlier treatment38,40 and studies that tested minimally
invasive approaches.18,30–32,38–41,44,45 As one-quarter of
patients with ICH show hematoma growth consistent
with ongoing bleeding in the first hours after symptom
onset, some neurosurgeons advocate postponing surgical
intervention until the hematoma has stabilized.23,24 The
nonrandomized pilot study of “ultra-early” open craniotomy
and hematoma evacuation (median time to surgery =
180 minutes) showed rebleeding in 4 of 11 patients and was
therefore stopped early.23 A recent study suggested that ste-
reotactic aspiration within 6 hours after symptom onset may
be safe in patients with sICH in the absence of a spot sign.24
However, it should be noted that in a recent individual
patient data meta-analysis of 5,435 patients assessing predic-
tion of hematoma growth, the addition of the CT angiogra-
phy spot sign to a prediction model with time from
symptom onset, ICH volume, anticoagulant use, and anti-
platelet use improved the C-index only slightly (from 0.78,
95% CI = 0.75–0.82 to 0.83, 95% CI = 0.80–0.86).19 The
risks of early hematoma growth and rebleeding after ultra-
early surgery have shaped the inclusion criterion of proof of a
stable ICH volume before starting any type of surgery in
recent and ongoing RCTs (MIND, NCT03342664)18,31,32
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and an ongoing nonrandomized trial (INVEST,
NCT02654015). However, theoretically early surgery could
also have additional benefits, such as prevention of ICH
growth, additional mass effect and raised intracranial pres-
sure, and amelioration of the secondary brain injury resulting
from the toxic effect of blood degradation products and the
inflammatory response after ICH. If the timing of surgery is
a key success factor, this would favor minimally invasive
techniques without the use of thrombolytic agents over pro-
cedures that include a time-consuming thrombolysis of the
hematoma to reach optimal evacuation. In MISTIE III, sur-
gical treatment was started on average 58.3 hours after symp-
tom onset, the first dose of alteplase was administered after
on average 72.6 hours, and treatment was completed after
on average after 123 hours.18 The prespecified subgroup
analysis on timing in the MISTIE III trial showed no effect
of timing of treatment, but none of the patients was treated
before 18 hours after symptom onset.18 A recent systematic
review comparing randomized controlled trials of minimally
invasive surgery versus conventional craniotomy, or versus
medical management, showed similar benefits for minimally
invasive surgery performed within 24 hours as for surgery
performed within 72 hours.49 However, this analysis differs
from ours in that it also included studies of minimally inva-
sive surgery compared to conventional craniotomy and by
their method of analyzing timing of surgery, including the
patients treated within 24 hours also in the group treated
within 72 hours. The results from our meta-regression sup-
port a potential beneficial effect from earlier surgery, but it is
important to note that the average time to surgery in all
studies but one43 was >8 hours. Furthermore, results of any
meta-regression analysis should be interpreted with caution,
because they are observational associations based on averages
at the study level and not based on individual patient data,
and the included studies have different inclusion and exclu-
sion criteria. Based on the combined evidence of this system-
atic review and meta-regression and that of others, further
well-designed randomized studies should be performed in
both the earlier and later time windows. The Dutch ICH
Surgery Trial pilot study (NCT03608423; part of the CON-
TRAST consortium; Dutch-ICH.nl) is currently assessing
safety, technical effectiveness, and feasibility of minimally
invasive endoscopy-guided surgery for sICH within 8 hours
of symptom onset, whereas others are assessing the effect of
minimally invasive surgery within 24 hours (MIND,
NCT03342664; INVEST, NCT02654015; ENRICH,
NCT02880878). Early treatment after sICH may pose a
logistical challenge in particular in countries with large dis-
tances between patients and neurosurgical centers. Public
policies of reimbursement of treatment only for patients who
are included in a randomized controlled trial may boost
recruitment rates.50
In contrast with the previous individual patient data
meta-analysis,17 we did not find a modifying effect of age
or the clinical state of the patient at admission. Based on
the results of our meta-regression analysis, we suggest that
there is no reason to exclude elderly patients from inclu-
sion in future RCTs, or to restrict inclusion to patients on
the basis of their GCS score. However, meta-regression
analysis is based on observational relations using averages
of potential modifying factors within studies and accord-
ingly limited ranges of the modifying factors. Therefore,
the observed relations across studies can be subject to con-
founding by other characteristics that vary between the
studies, and relations may not be undoubtedly causal (eco-
logical bias). Furthermore, the small number of studies
that reported modifying factors precluded multivariate
meta-regression analysis. Individual patient data meta-
analysis of all studies included in our meta-analysis could
strengthen our findings. STICH suggested a potential
modifying effect of sICH location in favor of lobar hemor-
rhages over deep sICH,15 but this could not be confirmed
by STICH II,16 nor by the individual patient data meta-
analysis.17 In contrast, our subgroup analysis showed a
beneficial effect of hematoma evacuation in patients with
deep hemorrhages, but not in those with lobar hemor-
rhages. A possible explanation is that the modifying effect
of location may vary between craniotomy and minimally
invasive hematoma evacuation.
Our study has several strengths. First, we performed
a comprehensive literature search without any language or
publication date restrictions. Second, we assessed the effect
of surgery aimed at hemorrhage evacuation overall, as well
as of minimally invasive techniques separately. Third, we
performed a sensitivity analysis in high-quality studies and
were able to assess modifying factors through meta-
regression analysis. Finally, in contrast to previous system-
atic reviews on minimally invasive surgery,49,51,52 we
excluded studies that compared minimally invasive tech-
niques to craniotomy.
Our study also has limitations, the most important
being the moderate to low quality of some of the included
studies. Only 5 studies performed blinded outcome
assessments,15,16,18,31,44 and only 4 studies were of high
quality overall.15,16,18,31 In addition, crossover to surgery
was high in some studies,15,16,38,39 and not reported in
many.32,34–37,40,42,44,45,47 Another limitation is that stud-
ies varied with respect to timing of both surgery and out-
come assessment, the definition of good functional
outcome, and the reporting of adverse events. Finally, the
use of averages of potential modifying factors in studies,
and not individual patient data in meta-regression analysis,
could have led to ecological bias. Because of this, we
refrained from translating the association to an estimate in
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terms of a quantitative effect per hour earlier that surgery
is commenced. Individual patient data meta-analysis of
the published RCTs could further inform us on whether a
larger benefit may be expected in specific subgroups, with
specific surgical approaches, or in a specific time-window,
without having the possible disadvantages of a meta-
regression analysis.
Taken together and despite the recent neutral results
of MISTIE III, the results of our systematic review and
meta-analysis suggest that surgical treatment may be bene-
ficial to improve outcome in patients with supratentorial
sICH, in particular with minimally invasive procedures
and when performed early after symptom onset. However,
because of the methodological shortcomings and high risk
of bias of most included studies, hematoma evacuation
cannot be recommended as standard treatment until fur-
ther high-quality RCTs have firmly proven its effect. Such
trials should have a large sample size, high adherence to
the intervention, focused hypothesis-testing, and blinded
outcome assessment.53 Physicians involved in the care of
patients with ICH should be encouraged to enroll patients
with a supratentorial sICH in trials investigating the bene-
fit of (minimally invasive) surgery.
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